PT-141
PT-141 (bremelanotide) is a melanocortin receptor agonist studied in research applications related to neural signaling pathways.
The best origin story in the whole series: it started life as a tanning drug, and the side effect became the product.
We have not published an audit on PT-141. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
PT-141 (bremelanotide) is a synthetic cyclic peptide that activates two melanocortin receptors in the brain, MC3R and MC4R, working through the central nervous system rather than by changing blood flow. [Source: Peptide Dosing Protocols]
PT-141 works by activating two receptors in the brain (MC3R and MC4R) to increase sexual desire through the central nervous system, not by changing blood flow like Viagra or Cialis.
Reported side effects
The most common side effects are nausea (in about 40% of users), flushing, headache, and injection site reactions, most of which are mild, decrease over time, and rarely cause people to stop using it.
Who should avoid it
People with uncontrolled high blood pressure, cardiovascular disease, pregnancy, or those who are postmenopausal or male should not use PT-141 per the FDA-approved label, and it should never be combined with other melanocortin agonists like Melanotan II.
What gets monitored
Blood pressure, nausea severity, and any darkening of the skin, gums, or breasts; clinician check-in suggested if condition has not improved after 8 weeks. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for PT-141 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 1.75 mg | not stated | subcutaneous or oral | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 1.75 mg | 1 dose per 24 hours8 doses per month | Subcutaneous (abdomen or thigh) | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). The standard dose of PT-141 is 1.75 mg subcutaneous at least 45 minutes before sexual activity. |
| Injection referenced at 0.5-2 mg per dose with onset in 1-4 hours, peak at 6-12 hours, duration 24-72 hours. Nasal spray referenced at 2-4 sprays per nostril, onset 30-60 minutes, duration 6-12 hours. Start low; side effects are dose-dependent (nausea most common). | As needed · On-demand, 1-4 hours before desired effect (injection) | subcutaneous or nasal | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- not stated
- subcutaneous or oral
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- 1 dose per 24 hours8 doses per month
- Subcutaneous (abdomen or thigh)
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). The standard dose of PT-141 is 1.75 mg subcutaneous at least 45 minutes before sexual activity.
- As needed · On-demand, 1-4 hours before desired effect (injection)
- subcutaneous or nasal
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- reconstitution math, route considerations, and side effects for this bremelanotide peptide.
Common questions
What is PT-141?
PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin MC3R and MC4R receptors in the brain.
What is the FDA-approved PT-141 dose?
The FDA-approved Vyleesi label lists 1.75 mg subcutaneous, given at least 45 minutes before sexual activity.
Is PT-141 approved for men?
No, the FDA approval is specifically for premenopausal women with HSDD.
Is PT-141 nasal spray FDA-approved?
No, the FDA-approved bremelanotide product is an injection (Vyleesi).
How long does PT-141 take to work?
The Vyleesi label and Phase 3 trial design use a ≥45-minute interval before sexual activity.
What are the most common side effects?
Nausea is the most common adverse event, reported in about 40% of users.
Who should avoid PT-141?
PT-141 should not be used by people with uncontrolled hypertension or known cardiovascular disease.
Can PT-141 be combined with sildenafil or tadalafil?
There is no formal clinical evidence combining PT-141 with PDE5 inhibitors.
Sources
- 01Mayo Clinic / Merative Micromedex Bremelanotide (subcutaneous route) — Description and Dosing. Mayo Clinic Drugs & Supplements (2026)
- 02Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology (2019)
- 03Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology (2019)
- 04Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health (London) (2016)
- 05Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research (2006)
- 06Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. Journal of Sexual Medicine (2008)
- 07Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences USA (2004)
- 08Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health (2022)
- 09Pfaus J, Giuliano F, Gelez H. Bremelanotide: An overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine (2007)
- 10Loti Labs (Editorial). PT-141 (Bremelanotide): Melanocortin Receptor Agonist Research Guide. Loti Labs Resources (2026)
The reference sections above are imported from our compound knowledge base, which classes the evidence for PT-141 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
AOD9604 is a modified C-terminal fragment of human growth hormone (residues 176-191), studied in lipid metabolism research models.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.